Antifungal Drug

This study explores transdermal insulin patch technology as a possible alternative to conventional subcutaneous insulin injections in managing diabetes mellitus. A quasi-experimental design was utilized in this study, comparing the efficacy, safety, patient satisfaction, and adherence of insulin patches with subcutaneous insulin injections. A total of 150 adults, 75 in each group, with a medical diagnosis of either Type 1 or Type 2 diabetes mellitus, were recruited from diabetes management clinics. Glycemic parameters were measured pre- and post-intervention for six months on both groups, including HbA1c and glucose levels while fasting. Results indicated that both the treatment groups revealed significant reductions in HbA1c and fasting glucose. The insulin patch group had an even more pronounced reduction in HbA1c and glucose levels. The insulin patch was well-tolerated, with only 12% of participants experiencing mild skin irritation. Patient satisfaction was significantly higher in the experimental group, with 88% rating the insulin patch as "very convenient" compared to 46% in the control group.

Itraconazole is a potent antifungal agent, which has poor solubility and high first-pass metabolism, thus limiting its oral bioavailability. The present research work focuses on the enhancement of itraconazole's bioavailability through the formulation and evaluation of a nanoemulsion. A nanoemulsion was prepared with the help of Tween 80, medium-chain triglycerides, and propylene glycol. It was ensured the stability of the drug was ensured through mean particle size, 180 nm, polydispersity index of 0.15, and zeta potential of -22.4 mV. In vitro drug release experiments showed that the amount released was 88% within 4 hours, which is significantly higher compared to the output from the basic suspension with around 50% release. The ex vivo permeation experiments showed improvement in the drug permeability, sixfold. Pharmacokinetic studies in rats demonstrated high values of the obtained peak concentrations C_max of 25.4 μg/ml, and AUC_0-∞ of 110.2 μg·hr/ml. Stability studies from three months' duration showed a broader durability of the formulation. Noticeably, the outcome is a novel agent in this clinical environment that can increase oral bioavailability and simultaneously enhance drug activity.